New consensus statements for therapeutic drug monitoring in patients receiving anti-TNF agents for their IBD will help optimise patient outcomes and rationalise use of the costly agents. The panel of Australian, New Zealand, US and Canadian experts agreed on 22 of the 24 statements drafted after an extensive literature review and modified Delphi process. They ...
High level of consensus on therapeutic drug monitoring for IBD
By Mardi Chapman
20 Oct 2017